Black Diamond Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
T. Rowe Price Investment Management, Inc. has reported beneficial ownership of 7.0% of Black Diamond Therapeutics' common stock as of June 30, 2026.
NASDAQ
SCHEDULE 13G/A: BlackRock Reduces Stake in Black Diamond Therapeutics to 4.5%
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 4.5% beneficial ownership stake in Black Diamond Therapeutics, Inc. as of March 31, 2025, indicating a reduction from a previously reportable position.
NASDAQ
BB Biotech AG and its wholly-owned subsidiary, Biotech Growth N.V., have reported a 4.8% beneficial ownership stake in Black Diamond Therapeutics, Inc. as of March 19, 2025.
NASDAQ
BB Biotech AG and its wholly-owned subsidiary, Biotech Growth N.V., have disclosed a combined beneficial ownership of 15.1% in Black Diamond Therapeutics, Inc., holding 8,517,839 shares of common stock as of December 31, 2024.